不眠症治療市場

Introduction

Approximately 50% of the population experience symptoms of insomnia on a regular basis. However, only a fraction of patients are diagnosed, with even fewer receiving prescribed pharmacological therapy. Currently Sanofi's Ambien (zolpidem) is the market leader across the seven major markets, with revenues of $1.7 billion in 2003.

Scope of this report

• Overview of the epidemiology of insomnia in order to assess the untapped patient potential offered by this disorder
• Analysis of why the US insomnia market has flourished, and of how similar success can be achieved in Europe in the future
• Evaluation of the current market leaders and primary contenders for entrance in to the market
• Assessment of product positioning and life-cycle management strategies of branded and pipeline manufacturers

Research and analysis highlights

• Datamonitor estimates that approximately 67 million insomnia patients will receive prescribed drug therapy in 2004 across the seven major markets, although the potential patient population is considerably higher at 238 million across the seven major markets.
• Ambien is currently the market-leading insomnia drug, with a 94% share of the branded insomnia market. However, the drug will face increasing competition with the launch of generic zolpidem and numerous novel drugs.
• Sepracor's Estorra and Neurocrine/Pfizer's indiplon are expected to reach market during 2005, and will drive the growth of the insomnia market, both reaching blockbuster status within the forecast period.

Key reasons to read this report

• Analyze the commercial viability of the insomnia market, based on estimated patient numbers, historical and forecast sales data
• Develop an understanding of key unmet needs of the insomnia market, market entry and consolidation strategies a current and future players
• Identify and assess novel R&D compounds in the insomnia pipeline

ABOUT DATAMONITOR HEALTHCARE

About the CNS pharmaceutical analysis team

EXECUTIVE SUMMARY

Introduction

Scope and coverage of the Brief

Key findings about the topic

Datamonitor estimates that approximately 67 million insomnia patients will receive prescribed drug therapy in 2004 across the seven major markets, although the potential patient population is considerably higher at 238 million across the seven major markets.

Ambien is currently the market-leading insomnia drug, with a 94% share of the branded insomnia market. However, the drug will face increasing competition with the launch of generic zolpidem and numerous novel drugs.

Sepracor's Estorra and Neurocrine/Pfizer's indiplon are expected to reach market during 2005, and will drive the growth of the insomnia market, both reaching blockbuster status within the forecast period.

DIESEASE OVERVIEW

Disease definition

Insomnia classification

Epidemiology

Prevalence of insomnia

Gender

Diagnosis and diagnosis rates

Treatment

Economic consequences

Summary of patient potential

PHARMACOLOGICAL THERAPY

Benzodiazepines

Drugs used off-label

Antihistamines

Antidepressants

Unmet needs in insomnia

BRANDED INSOMNIA DRUGS

Ambien/Stilnox (zolpidem)

Marketing strategies

Reformulation

Demonstrate long-term efficacy and safety of Ambien

Sanofi-Aventis and insomnia

Sonata (zaleplon)

Marketing strategies

Current market overview

US market

Japanese market

European market

PIPELINE COMPOUNDS

Indiplon

Marketing strategies

Estorra (eszopiclone)

Marketing strategies

Estorra versus Indiplon

TAK-375

Gaboxadol

FUTURE PERSPECTIVE

Reformulation strategies

Sonata

Ambien CR

Free drug trials

Targeting US employers

Insomnia market forecast

APPENDIX

Contributing experts

Bibliography

Websites

Research methodology

Disclaimer

List of Tables

Table 1: Insomnia patient populations (000s) across the seven major markets, 2004

Table 2: Marketed insomnia drugs' revenues in the US, Japan and five major European markets ($m), 1999-2003

Table 3: Insomnia R&D pipeline, 2004

Table 4: Insomnia market forecast, 2003-12 ($m)

List of Figures

Figure 1: Symptoms of insomnia in the US population

Figure 2: Characteristics of the ideal hypnotic drug, 2004

Figure 3: Impact of generic of Zimovane revenues in the five major European markets

Figure 4: Revenues of Ambien, Sonata and other marketed insomnia drugs in the US, Japan and five major European markets ($m), 1999-2003

Figure 5: Ambien free trial offer

Figure 6: Insomnia market forecast, 2004-12